These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 12386211)

  • 1. Section II. Haemodialysis adequacy.
    European Best Practice Guidelines Expert Group on Hemodialysis, European Renal Association
    Nephrol Dial Transplant; 2002; 17 Suppl 7():16-31. PubMed ID: 12386211
    [No Abstract]   [Full Text] [Related]  

  • 2. Do we need new indicators of dialysis adequacy based on middle-molecule removal?
    Vanholder R; Eloot S; Van Biesen W
    Nat Clin Pract Nephrol; 2008 Apr; 4(4):174-5. PubMed ID: 18268526
    [No Abstract]   [Full Text] [Related]  

  • 3. Adequacy of dialysis: a critical analysis.
    Vanholder RC; Ringoir SM
    Kidney Int; 1992 Sep; 42(3):540-58. PubMed ID: 1405333
    [No Abstract]   [Full Text] [Related]  

  • 4. Reduction of echinocytes post-haemodialysis.
    Calzavara P; Amici G; Calconi G; De Angeli S; Da Rin G; Furlan C
    Nephrol Dial Transplant; 1995; 10(5):716-7. PubMed ID: 7566595
    [No Abstract]   [Full Text] [Related]  

  • 5. Dialysis therapy: 'think differently'.
    Perrone B
    Nephrol Dial Transplant; 2007 Jul; 22 Suppl 5():v1-2. PubMed ID: 17586840
    [No Abstract]   [Full Text] [Related]  

  • 6. [Subacute glomerulonephritis--a contradiction to intermittent haemodialysis?].
    Lindqvist B; Michaelsson G; Nyström K
    Nord Med; 1967 Jul; 78(28):901-2. PubMed ID: 6028541
    [No Abstract]   [Full Text] [Related]  

  • 7. Regression of uraemic pruritus by cyclosporin treatment in a haemodialysis patient.
    Fusaro M; Munaretto G; Spinello M; Gallieni M
    Nephrol Dial Transplant; 2004 May; 19(5):1338-9. PubMed ID: 15102989
    [No Abstract]   [Full Text] [Related]  

  • 8. Prevention of clot formation during haemodialysis using the direct thrombin inhibitor melagatran in patients with chronic uraemia.
    Attman PO; Ottosson P; Samuelsson O; Eriksson UG; Eriksson-Lepkowska M; Fager G
    Nephrol Dial Transplant; 2005 Sep; 20(9):1889-97. PubMed ID: 15928099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma ghrelin levels in patients undergoing haemodialysis and peritoneal dialysis.
    Pérez-Fontán M; Cordido F; Rodríguez-Carmona A; Peteiro J; García-Naveiro R; García-Buela J
    Nephrol Dial Transplant; 2004 Aug; 19(8):2095-100. PubMed ID: 15187192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors of the progression of abdominal aortic calcification in patients on chronic haemodialysis.
    Shahapuni I; Esper NE; Opisiv R; Massy Z; Choukroun G; Garabedian M; Fournier A
    Nephrol Dial Transplant; 2008 Apr; 23(4):1456-7; author reply 1457-8. PubMed ID: 18039645
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of L-carnitine administration on erythropoietin use in thalassemic minor haemodialysis patients.
    Di Iorio BR; Guastaferro P; Cillo N; Cucciniello E; Bellizzi V
    Nephrol Dial Transplant; 2007 Mar; 22(3):954-5; author reply 955-6. PubMed ID: 17132710
    [No Abstract]   [Full Text] [Related]  

  • 12. Continuous arteriovenous haemodialysis.
    BMJ; 1988 Sep; 297(6648):616-7. PubMed ID: 3139237
    [No Abstract]   [Full Text] [Related]  

  • 13. [Quantifying dialysis efficiency for middle molecules in haemodialysis and in convective and mixed techniques].
    Casino FG; Lopez T
    G Ital Nefrol; 2008; 25(1):66-75. PubMed ID: 18264920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain dysfunction in uremia: a question of cortical hyperexcitability?
    Battaglia F; Quartarone A; Bagnato S; Rizzo V; Morgante F; Floccari F; Romeo A; Sant'Angelo A; Grasso G; Girlanda P; Buemi M
    Clin Neurophysiol; 2005 Jul; 116(7):1507-14. PubMed ID: 15908270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of L-carnitine administration on erythrocyte survival in haemodialysis patients.
    Arduini A; Bonomini M; Clutterbuck EJ; Laffan MA; Pusey CD
    Nephrol Dial Transplant; 2006 Sep; 21(9):2671-2. PubMed ID: 16611680
    [No Abstract]   [Full Text] [Related]  

  • 16. Iron supplementation and oxidative stress in patients with uremia.
    Shetty JK; Prakash M
    Indian J Physiol Pharmacol; 2007; 51(2):179-82. PubMed ID: 18175664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemodialysis adequacy: basic essentials and practical points for the nephrologist in training.
    Depner TA
    Hemodial Int; 2005 Jul; 9(3):241-54. PubMed ID: 16191074
    [No Abstract]   [Full Text] [Related]  

  • 18. Prevention of clot formation during haemodialysis using the direct thrombin inhibitor melagatran in patients with chronic uraemia.
    Attman PO
    Nephrol Dial Transplant; 2006 Jun; 21(6):1738. PubMed ID: 16364986
    [No Abstract]   [Full Text] [Related]  

  • 19. Adequacy of treatment of uremia in the nineties.
    David S; Cambi V
    Contrib Nephrol; 1993; 103():1-9. PubMed ID: 8354052
    [No Abstract]   [Full Text] [Related]  

  • 20. The ineffectiveness of haemodialysis in removing peptides inhibiting glucose utilisation.
    Dzúrik R; Adam J; Reznícek J
    Proc Eur Dial Transplant Assoc; 1972; 9():142-6. PubMed ID: 4668906
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.